Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PETER H WIN

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1124040209
CMS profile
141025
Location
ARCADIA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$369.48

18 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $268.44 14
Gift $101.04 4

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PETER H WIN

NPI 1124040209 · CMS profile ID 141025

Allopathic & Osteopathic Physicians / Ophthalmology

ARCADIA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124040209?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PETER H WIN, NPI 1124040209, CMS profile ID 141025. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124040209?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). PETER H WIN, NPI 1124040209, CMS profile ID 141025. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124040209?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
PETER H WIN, NPI 1124040209, CMS profile ID 141025, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1124040209?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

18 matching records · $369.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 18 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–18 of 18.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Sun Pharmaceutical Industries Inc. $23.7812/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728252815 CMS
Sun Pharmaceutical Industries Inc. $22.1312/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728252817 CMS
Bausch & Lomb, a division of Bausch Health US, LLC $13.1111/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737424091 CMS
Allergan, Inc. $13.7711/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723843981 CMS
Aerie Pharmaceuticals, Inc. $21.4211/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742476235 CMS
Allergan, Inc. $13.9210/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723843979 CMS
Allergan, Inc. $22.9609/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723843977 CMS
Bausch & Lomb, a division of Bausch Health US, LLC $13.8808/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737424089 CMS
Bausch & Lomb, a division of Bausch Health US, LLC $12.3608/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737424087 CMS
Sun Pharmaceutical Industries Inc. $21.9608/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728252819 CMS
Aerie Pharmaceuticals, Inc. $24.9308/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742476217 CMS
Allergan, Inc. $45.0008/03/2020 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723843975 CMS
Sun Pharmaceutical Industries Inc. $20.8806/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728252821 CMS
Carl Zeiss Meditec, Inc. $17.2405/13/2020 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749001873 CMS
Carl Zeiss Meditec AG $19.4005/08/2020 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728024929 CMS
Carl Zeiss Meditec AG $19.4005/08/2020 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728024931 CMS
Aerie Pharmaceuticals, Inc. $24.1902/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742476205 CMS
Allergan, Inc. $19.1501/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723843973 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $376.26 27
PY2020 $369.48 18
PY2021 $467.02 31
PY2022 $408.04 22
PY2023 $529.17 23
PY2024 $307.75 14
PY2025 $396.97 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,800.65 3
PY2025 Principal investigator $1,018,714.70 358
PY2024 Recipient $41,692.12 4
PY2024 Principal investigator $792,747.79 884
PY2023 Recipient $95,996.85 6
PY2023 Principal investigator $408,946.29 24
PY2022 Recipient $123,777.97 8
PY2022 Principal investigator $843,108.89 22
PY2021 Principal investigator $927,697.26 16
PY2020 Principal investigator $132,922.86 4
PY2019 Principal investigator $29,997.25 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

361 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 12/31/2025 Non-covered Recipient Entity
Win Retina-Arcadia
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220679340
Recipient Regeneron Pharmaceuticals, Inc. $431.65 12/27/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184123946
Principal investigator 1 KYOWA KIRIN, INC. $1,958.23 12/19/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221814713
Principal investigator 1 KYOWA KIRIN, INC. $1,958.23 12/19/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221814722
Principal investigator 1 KYOWA KIRIN, INC. $1,161.45 12/19/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814732
Principal investigator 1 KYOWA KIRIN, INC. $2,000.28 12/19/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221814740
Principal investigator 1 KYOWA KIRIN, INC. $4,688.58 12/19/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221814748
Principal investigator 1 KYOWA KIRIN, INC. $2,865.13 12/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814443
Principal investigator 1 KYOWA KIRIN, INC. $2,677.21 12/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814452
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 12/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814458
Principal investigator 1 KYOWA KIRIN, INC. $2,865.13 12/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814467
Principal investigator 1 KYOWA KIRIN, INC. $4,476.81 12/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814473
Principal investigator 1 KYOWA KIRIN, INC. $5,586.71 12/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814481
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 12/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814488
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273792
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273794
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273796
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273800
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273802
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273816
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273828
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273832
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273834
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273836
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273838
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273840
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273842
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273844
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,393.96 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273846
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273848
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273850
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273854
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,393.96 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273856
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273858
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273860
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,393.96 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273862
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273864
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273866
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273868
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273870
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273872
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,554.97 12/11/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184273876
Principal investigator 1 KYOWA KIRIN, INC. $695.00 11/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221814365
Principal investigator 1 KYOWA KIRIN, INC. $250.00 11/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221814371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,950.00 11/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184266279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 11/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184266281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 11/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184266283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 11/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184266285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,000.00 11/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184266287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,013.90 11/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184261659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,013.90 11/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184261661
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 10/31/2025 Non-covered Recipient Entity
Win Retina-Arcadia
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220679336
Principal investigator 1 KYOWA KIRIN, INC. $39,358.75 10/30/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221813896
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 10/28/2025 Non-covered Recipient Entity
Win Retina-Arcadia
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220679338
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 10/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812320
Principal investigator 1 KYOWA KIRIN, INC. $2,865.13 10/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812329
Principal investigator 1 KYOWA KIRIN, INC. $2,677.21 10/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812339
Principal investigator 1 KYOWA KIRIN, INC. $3,800.16 10/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812349
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 10/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812357
Principal investigator 1 KYOWA KIRIN, INC. $2,677.21 10/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812363
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 10/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812383
Principal investigator 1 KYOWA KIRIN, INC. $2,845.56 10/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812393
Principal investigator 1 KYOWA KIRIN, INC. $1,161.45 10/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812410
Principal investigator 1 KYOWA KIRIN, INC. $2,677.21 10/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812422
Principal investigator 1 KYOWA KIRIN, INC. $1,161.45 10/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812432
Principal investigator 1 KYOWA KIRIN, INC. $1,161.45 10/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812440
Principal investigator 1 KYOWA KIRIN, INC. $5,560.61 10/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812450
Principal investigator 1 KYOWA KIRIN, INC. $1,161.45 10/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812467
Principal investigator 1 KYOWA KIRIN, INC. $2,677.21 10/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812476
Principal investigator 1 KYOWA KIRIN, INC. $4,476.81 10/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812486
Principal investigator 1 KYOWA KIRIN, INC. $4,104.95 10/03/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221811007
Principal investigator 1 KYOWA KIRIN, INC. $5,586.71 10/03/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221811014
Principal investigator 1 KYOWA KIRIN, INC. $4,104.95 10/03/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221811023
Principal investigator 1 KYOWA KIRIN, INC. $1,958.23 10/03/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221811029
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 09/30/2025 Non-covered Recipient Entity
Win Retina-Arcadia
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220679324
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239684
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239686
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239688
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239692
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,105.90 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239694
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239696
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239700
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239702
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,105.90 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239706
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239708
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239710
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,105.90 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239712
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239714
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239716
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 09/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239718
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 08/29/2025 Non-covered Recipient Entity
Win Retina-Arcadia
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220679326
Principal investigator 1 KYOWA KIRIN, INC. $5,008.59 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221809983
Principal investigator 1 KYOWA KIRIN, INC. $5,008.59 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221809990
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221809997
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810004
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810011
Principal investigator 1 KYOWA KIRIN, INC. $4,476.81 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810020
Principal investigator 1 KYOWA KIRIN, INC. $2,865.13 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810028
Principal investigator 1 KYOWA KIRIN, INC. $5,008.59 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810035
Principal investigator 1 KYOWA KIRIN, INC. $5,008.59 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810042
Principal investigator 1 KYOWA KIRIN, INC. $2,865.13 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810049
Principal investigator 1 KYOWA KIRIN, INC. $2,677.21 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810056
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810064
Principal investigator 1 KYOWA KIRIN, INC. $2,677.21 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810070
Principal investigator 1 KYOWA KIRIN, INC. $5,008.59 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810079
Principal investigator 1 KYOWA KIRIN, INC. $2,845.56 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810086
Principal investigator 1 KYOWA KIRIN, INC. $2,845.56 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810094
Principal investigator 1 KYOWA KIRIN, INC. $5,008.59 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810103
Principal investigator 1 KYOWA KIRIN, INC. $2,845.56 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810111
Principal investigator 1 KYOWA KIRIN, INC. $5,008.59 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810117
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810124
Principal investigator 1 KYOWA KIRIN, INC. $5,008.59 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810133
Principal investigator 1 KYOWA KIRIN, INC. $5,560.61 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810141
Principal investigator 1 KYOWA KIRIN, INC. $3,800.16 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810148
Principal investigator 1 KYOWA KIRIN, INC. $2,677.21 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810154
Principal investigator 1 KYOWA KIRIN, INC. $2,845.56 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810162
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810171
Principal investigator 1 KYOWA KIRIN, INC. $5,560.61 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810178
Principal investigator 1 KYOWA KIRIN, INC. $5,560.61 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810185
Principal investigator 1 KYOWA KIRIN, INC. $3,800.16 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810192
Principal investigator 1 KYOWA KIRIN, INC. $2,677.21 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810200
Principal investigator 1 KYOWA KIRIN, INC. $4,476.81 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810207
Principal investigator 1 KYOWA KIRIN, INC. $3,800.16 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810212
Principal investigator 1 KYOWA KIRIN, INC. $5,560.61 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810221
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810228
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810237
Principal investigator 1 KYOWA KIRIN, INC. $2,677.21 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810245
Principal investigator 1 KYOWA KIRIN, INC. $5,008.59 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810254
Principal investigator 1 KYOWA KIRIN, INC. $2,845.56 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810263
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810273
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810282
Principal investigator 1 KYOWA KIRIN, INC. $5,560.61 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810293
Principal investigator 1 KYOWA KIRIN, INC. $4,476.81 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810297
Principal investigator 1 KYOWA KIRIN, INC. $2,677.21 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810305
Principal investigator 1 KYOWA KIRIN, INC. $2,677.21 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810313
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 08/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810323
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 08/26/2025 Non-covered Recipient Entity
Win Retina-Arcadia
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220679328
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 08/26/2025 Non-covered Recipient Entity
Win Retina-Arcadia
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220679330
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 08/26/2025 Non-covered Recipient Entity
Win Retina-Arcadia
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220679332
Principal investigator 1 Boehringer Ingelheim International GmbH $43.70 08/26/2025 Non-covered Recipient Entity
Win Retina-Arcadia
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220679334
Principal investigator 1 Boehringer Ingelheim International GmbH $95.01 08/21/2025 Non-covered Recipient Entity
Win Retina-Arcadia
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220679320
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 08/21/2025 Non-covered Recipient Entity
Win Retina-Arcadia
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220679322
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223664
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223682
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223684
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223686
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223792
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223794
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,920.24 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223796
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223800
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223872
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223874
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223876
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223968
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223970
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 08/06/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223972
Recipient Genentech, Inc. $2,725.00 08/01/2025 Covered Recipient Physician Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211538209
Principal investigator 1 KYOWA KIRIN, INC. $2,000.28 07/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807096
Principal investigator 1 KYOWA KIRIN, INC. $2,272.88 07/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807103
Principal investigator 1 KYOWA KIRIN, INC. $1,958.23 07/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807109
Principal investigator 1 KYOWA KIRIN, INC. $2,000.28 07/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807117
Principal investigator 1 KYOWA KIRIN, INC. $3,161.73 07/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807126
Principal investigator 1 KYOWA KIRIN, INC. $6,751.20 07/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807134
Principal investigator 1 KYOWA KIRIN, INC. $2,974.68 07/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807142
Principal investigator 1 KYOWA KIRIN, INC. $4,688.58 07/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807149
Principal investigator 1 KYOWA KIRIN, INC. $2,272.88 07/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807157
Principal investigator 1 KYOWA KIRIN, INC. $1,958.23 07/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807163
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806916
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806923
Principal investigator 1 KYOWA KIRIN, INC. $3,800.16 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806932
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806938
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806948
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806953
Principal investigator 1 KYOWA KIRIN, INC. $3,800.16 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806960
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806966
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806973
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806979
Principal investigator 1 KYOWA KIRIN, INC. $3,800.16 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806988
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806999
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221807006
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221807015
Principal investigator 1 KYOWA KIRIN, INC. $3,800.16 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221807024
Principal investigator 1 KYOWA KIRIN, INC. $3,800.16 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221807030
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221807040
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221807047
Principal investigator 1 KYOWA KIRIN, INC. $5,586.71 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221807053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216508
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216514
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216516
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 07/16/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,105.90 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,105.90 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,105.90 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,105.90 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,105.90 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 06/02/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202331
Principal investigator 1 KYOWA KIRIN, INC. $18,892.20 05/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806077
Principal investigator 1 KYOWA KIRIN, INC. $2,000.28 04/28/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221804432
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 04/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 04/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188869
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 04/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 04/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 04/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 04/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 04/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 04/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 04/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 04/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 04/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 04/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 04/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 04/23/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184188893
Principal investigator 1 KYOWA KIRIN, INC. $5,586.71 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803394
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803401
Principal investigator 1 KYOWA KIRIN, INC. $2,677.21 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803411
Principal investigator 1 KYOWA KIRIN, INC. $3,800.16 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803419
Principal investigator 1 KYOWA KIRIN, INC. $2,677.21 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803426
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803435
Principal investigator 1 KYOWA KIRIN, INC. $2,865.13 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803444
Principal investigator 1 KYOWA KIRIN, INC. $5,586.71 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803452
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803460
Principal investigator 1 KYOWA KIRIN, INC. $3,800.16 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803468
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803476
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803484
Principal investigator 1 KYOWA KIRIN, INC. $3,800.16 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803492
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803498
Principal investigator 1 KYOWA KIRIN, INC. $5,586.71 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803506
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803515
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803526
Principal investigator 1 KYOWA KIRIN, INC. $2,677.21 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803534
Principal investigator 1 KYOWA KIRIN, INC. $3,800.16 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803541
Principal investigator 1 KYOWA KIRIN, INC. $2,865.13 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803549
Principal investigator 1 KYOWA KIRIN, INC. $5,560.61 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803560
Principal investigator 1 KYOWA KIRIN, INC. $1,956.85 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803569
Principal investigator 1 KYOWA KIRIN, INC. $5,586.71 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803576
Principal investigator 1 KYOWA KIRIN, INC. $2,845.56 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803581
Principal investigator 1 KYOWA KIRIN, INC. $2,277.88 04/17/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803589
Principal investigator 1 KYOWA KIRIN, INC. $3,790.30 03/31/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802488
Principal investigator 1 KYOWA KIRIN, INC. $2,314.93 03/31/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802496
Principal investigator 1 KYOWA KIRIN, INC. $2,000.28 03/31/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802504
Principal investigator 1 KYOWA KIRIN, INC. $3,790.30 03/31/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802513
Principal investigator 1 KYOWA KIRIN, INC. $5,921.80 03/31/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221802522
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 03/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172338
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 03/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172340
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 03/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172388
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 03/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172390
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 03/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172392
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 03/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172396
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 03/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172398
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 03/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172400
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 03/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172402
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 03/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172404
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 03/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172406
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 03/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172408
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,146.57 03/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172410
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 03/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172412
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 03/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172414
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 03/12/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172418
Recipient Genentech, Inc. $8,644.00 03/11/2025 Covered Recipient Physician Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211538205
Principal investigator 1 KYOWA KIRIN, INC. $3,148.70 01/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221799983
Principal investigator 1 KYOWA KIRIN, INC. $1,574.35 01/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221799990
Principal investigator 1 KYOWA KIRIN, INC. $3,148.70 01/27/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.44 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149470
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149472
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149474
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149476
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149478
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149480
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,720.28 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149482
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149484
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149486
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149488
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149490
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149492
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149494
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149496
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149498
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149500
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149502
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149504
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149506
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149508
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,720.28 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,720.28 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,720.28 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149514
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,720.28 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149516
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,720.28 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.32 01/24/2025 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184149520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 01/08/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184147241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 01/08/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184147243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,526.62 01/08/2025 Non-covered Recipient Entity
WIN RETINA
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184147245